Kiniksa Pharmaceuticals International plc
For the period ended Jun 30, 2024. Filed Jul 25, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Jul 25, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Trading Arrangements
The following table shows the “Rule 10b5-1 trading arrangements” or “non-Rule 10b5-1 trading arrangements” (as each term is defined in Item 408(a) of Regulation S-K) adopted, amended or terminated by our directors and officers during the three months ended June 30, 2024:
| · · · · Trading Arrangement · · | |||||||
|---|---|---|---|---|---|---|---|
| Name | Title | Action | Effective Date | Rule 10b5-1 | Non Rule 10b5-1 | Scheduled Expiration Date of Trading Plan(1) | Maximum Shares Subject to Trading Plan |
| Sanj K. Patel | Chief Executive Officer and Chairman of the Board | Adoption | April 25, 2024 | X | | October 17, 2024 | 325,271 |
| Eben Tessari | SVP, Chief Operating Officer | Adoption | April 29, 2024 | X | | December 18, 2025 | 715,680 |
| Ross Moat | SVP, Chief Commercial Officer | Adoption | May 3, 2024 | X | | April 17, 2025 | 109,506 |
| John Paolini | SVP, Chief Medical Officer | Adoption | May 16, 2024 | X | | October 17, 2024 | 112,217 |
| (1) | A trading arrangement may expire on an earlier date if all contemplated transactions are completed before such trading arrangement’s expiration date, upon termination by broker or the holder of the trading arrangement or as otherwise provided in the trading arrangement. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.